IDENTIFYING AND CHARACTERIZING METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) POPULATION IN FINLAND

被引：0
|
作者：
Ruotsalainen, J. [1 ]
Korhonen, M. J. [2 ]
Purmonen, T. [2 ]
Joutseno, J. [3 ]
Saavuori, N. [3 ]
机构：
[1] Oriola, Kuopio, Finland
[2] Oriola, Espoo, Finland
[3] Bayer, Espoo, Finland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD161
引用
收藏
页码：S535 / S535
页数：1
相关论文
共 50 条
  • [31] ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Saad, Fred
    Hussain, Maha
    Sternberg, Cora N.
    Fizazi, Karim
    Yamada, Karin Sayuri
    Kappeler, Christian
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [32] Cytoreductive radical prostatectomy (cRP) in the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
    Heidenreich, Axel
    Rieger, Constantin
    Kastner, Lucas
    Seelemeyer, Felix
    Pfister, David
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [33] Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
    Halabi, Susan
    Roy, Akash
    Guo, Siyuan S.
    Rydzewska, Larysa
    Godolphin, Peter
    Hussain, Maha H. A.
    Tangen, Catherine
    Thompson, Ian
    Xie, Wanling
    Carducci, Michael Anthony
    Smith, Matthew Raymond
    Morris, Michael J.
    Gravis, Gwenaelle
    Dearnaley, David P.
    Verhagen, Paul
    Goto, Takayuki
    Tierney, Jayne F.
    James, Nicholas D.
    Buyse, Marc E.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?
    Thomas, Christian
    Baunacke, Martin
    Erb, Holger H. H.
    Fuessel, Susanne
    Erdmann, Kati
    Putz, Juliane
    Borkowetz, Angelika
    CANCERS, 2022, 14 (01)
  • [35] ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Saad, Fred
    Hussain, Maha
    Sternberg, Cora N.
    Fizazi, Karim
    Crawford, E. David
    Yamada, Karin Sayuri
    Kappeler, Christian
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC)
    Omrcen, Tomislav
    ACTA CLINICA CROATICA, 2022, 61 : 81 - 85
  • [37] Diagnosis and staging of metastatic hormone-sensitive prostate cancer
    Krausewitz, Philipp
    Ritter, Manuel
    Essler, Markus
    UROLOGIE, 2023, 62 (04): : 347 - 353
  • [38] Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).
    Albiges, Laurence
    Xie, Wanling
    Chen, Yu-Hui
    Boher, Jean-Marie
    Valenca, Loana Bueno
    Bernard, Brandon David
    Culine, Stephane
    Habibian, Muriel
    Carducci, Michael Anthony
    DiPaola, Robert S.
    Liu, Glenn
    Pomerantz, Mark
    Nakabayashi, Mari
    Kantoff, Philip W.
    Fizazi, Karim
    Gravis, Gwenaelle
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Triple therapy in metastatic hormone-sensitive prostate cancer
    Tsaur, Igor
    Mirvald, Cristian
    Surcel, Cristian
    CURRENT OPINION IN UROLOGY, 2023, 33 (06) : 452 - 457
  • [40] Approval for Zytiga® in metastatic hormone-sensitive Prostate Cancer
    Junker, Annette
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (03) : 152 - 152
12345